Evidence map›Paper›PMID 34982285›Full record

ArticleThe AAPS journal2022

Dissolution Challenges Associated with the Surface pH of Drug Particles: Integration into Mechanistic Oral Absorption Modeling.

Bart Hens, Nidhi Seegobin, Marival Bermejo, Yasuhiro Tsume, Nicola Clear, Mark McAllister, Gregory E Amidon, Gordon L Amidon

Abstract read
PubMed Publisher
In one paragraph

Article in The AAPS journal, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed.

  1. Article
  2. Review
  3. Review
  4. Article
  5. Review
  6. Article
  7. Article
  8. Review
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Bart HensDrug Product Design, Pfizer, Discovery Park, Ramsgate Road, Sandwich, CT13 9ND, UK. bart.hens@pfizer.com.
Nidhi SeegobinDrug Product Design, Pfizer, Discovery Park, Ramsgate Road, Sandwich, CT13 9ND, UK.
Marival BermejoDepartment of Engineering, Pharmacy Section, Miguel Hernandez University, 03550, San Juan de Alicante, Alicante, Spain.
Yasuhiro TsumeMerck & Co., Inc, 126 E Lincoln Ave, Rahway, New Jersey, 07065, USA.
Nicola ClearDrug Product Design, Pfizer, Discovery Park, Ramsgate Road, Sandwich, CT13 9ND, UK.
Mark McAllisterDrug Product Design, Pfizer, Discovery Park, Ramsgate Road, Sandwich, CT13 9ND, UK.
Gregory E AmidonDepartment of Pharmaceutical Sciences, College of Pharmacy, University of Michigan, 428 Church Street, Ann Arbor, Michigan, 48109-1065, USA.
Gordon L AmidonDepartment of Pharmaceutical Sciences, College of Pharmacy, University of Michigan, 428 Church Street, Ann Arbor, Michigan, 48109-1065, USA. glamidon@med.umich.edu.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The present work aimed to differentiate between in vitro dissolution profiles of ibuprofen as input for GastroPlus™ and to see the impact on systemic exposure. In vitro dissolution profiles of ibuprofen obtained under low- and high-buffered dissolution media were used as input using the z-factor approach. In a second step, a customized surface pH calculator was applied to predict the surface pH of ibuprofen under these low- and high-buffered dissolution conditions. These surface pH values were adopted in GastroPlus™ and simulations were performed to predict the systemic outcome. Simulated data were compared with systemic data of ibuprofen obtained under fasted state conditions in healthy subjects. The slower dissolution rate observed when working under low-buffered conditions nicely matched with the slower dissolution rate as observed during the clinical aspiration study and was in line with the systemic exposure of the drug. Finally, a population simulation was performed to explore the impact of z-factor towards bioequivalence (BE) criteria (so-called safe space). Concerning future perspectives, the customized calculator should be developed in such a way to make it possible to predict the dissolution rate (being informed by the particle size distribution) which, in its turn, can be used as a surrogate to predict the USP2 dissolution curve. Subsequently, validation can be done by using this profile as input for PBPK platforms.

Indexed as

Models, BiologicalAdministration, OralChemistry, PharmaceuticalComputer SimulationDrug LiberationHumansHydrogen-Ion ConcentrationIbuprofenSolubilityTherapeutic EquivalencyIbuprofengastrointestinalgastroplusibuprofenoral drug absorptionphysiologically based biopharmaceutics modelingphysiologically based pharmacokinetic modelingsurface pH

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.